Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership
Lonza Pharma & Biotech and Denali Therapeutics (NASDAQ:DNLI) announced an exclusive strategic partnership on Denali’s biologic pipeline products for neurodegenerative diseases. The agreement covers all stages of the development and manufacturing. As quoted in the press release: Through this partnership Denali will have access to Lonza’s extensive expertise and technologies: from cell-line development using the …
Lonza Pharma & Biotech and Denali Therapeutics (NASDAQ:DNLI) announced an exclusive strategic partnership on Denali’s biologic pipeline products for neurodegenerative diseases. The agreement covers all stages of the development and manufacturing.
As quoted in the press release:
Through this partnership Denali will have access to Lonza’s extensive expertise and technologies: from cell-line development using the GS Xceed® Gene Expression System to process development and manufacturing at facilities in Slough (UK) and Hayward, CA (USA). In addition, Lonza’s in-house Drug Product Services in Basel (CH) will focus on ensuring that Denali’s finished product candidates are designed with optimal formulation, stability and delivery system in mind.